Hemerion develops a biotechnology platform that utilizes a photosensitizing drug combined with photonics to selectively target and destroy glioblastoma cells in areas inaccessible to traditional surgery, while preserving healthy tissue. This technology addresses the critical challenge of effectively treating brain cancer, offering a promising alternative to existing therapeutic options.
Funding
$8.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Glioblastoma, the most common form of brain cancer, presents a significant therapeutic challenge due to its aggressive nature and the difficulty in accessing affected areas of the brain without damaging healthy tissue. Current treatments often fail to completely eradicate the tumor, leading to recurrence and poor patient outcomes.
Solution
Hemerion is developing a biotechnology platform, Pentalafen® / Heliance®, that combines a photosensitizing drug with a photonics system to selectively target and destroy glioblastoma cells. The photosensitizing drug is administered and then activated by a specific wavelength of light delivered via the Heliance® illumination platform. This targeted approach allows for the destruction of tumor cells in areas that are difficult to reach with traditional surgery, while minimizing damage to surrounding healthy brain tissue. The therapy is currently in clinical trials with the goal of improving patient survival and quality of life.
Target Audience
The primary target audience includes neuro-oncologists, hospitals, and cancer centers specializing in the treatment of glioblastoma, as well as patients diagnosed with this aggressive form of brain cancer.
Features
- Pentalafen® photosensitizing drug selectively absorbed by glioblastoma cells
- Heliance® photonics system delivers targeted illumination to activate the drug
- Precise targeting minimizes damage to healthy brain tissue
- Potential to treat tumors in surgically inaccessible areas
- Clinical trials underway to evaluate safety and efficacy
- Intended to complement existing glioblastoma treatment options
- Protected by several trademarks and patents